Finding second hits to knock out leukemia
Targeted drugs are a cornerstone of personalized medicine, yet come with important drawbacks. They restrain disease progression – but rarely eradicate the cancer. Patients therefore need to take the drugs essentially forever, exposing them to severe side effects and incurring high costs for the healthcare system. Combination therapies could potentially overcome these limitations. A study by scientists from CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences in collaboration with the Medical University of Vienna shows how epigenetic analysis and automated microscopy help prioritize new drug combinations for leukemia therapy. The results were published in Nature Chemical Biology. (DOI: 10.1038/s41589-018-0205-2) on 28 January 2019.